GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Shiller PE Ratio

Acorda Therapeutics (FRA:CDG) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Acorda Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Acorda Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Shiller PE Ratio Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acorda Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acorda Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Shiller PE Ratio falls into.



Acorda Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Acorda Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Acorda Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Acorda Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 9.715 100.560 12.731
201409 26.074 100.428 34.213
201412 0.973 99.070 1.294
201503 -7.762 99.621 -10.267
201506 2.138 100.684 2.798
201509 9.623 100.392 12.631
201512 23.134 99.792 30.549
201603 -1.078 100.470 -1.414
201606 -42.720 101.688 -55.360
201609 -29.938 101.861 -38.730
201612 -7.963 101.863 -10.301
201703 -46.002 102.862 -58.933
201706 -19.224 103.349 -24.512
201709 -55.374 104.136 -70.072
201712 -375.179 104.011 -475.331
201803 -17.518 105.290 -21.925
201806 100.666 106.317 124.772
201809 -29.824 106.507 -36.900
201812 21.096 105.998 26.226
201903 -106.200 107.251 -130.485
201906 -61.596 108.070 -75.108
201909 -604.727 108.329 -735.614
201912 149.040 108.420 181.147
202003 -14.661 108.902 -17.741
202006 -38.894 108.767 -47.122
202009 5.434 109.815 6.521
202012 -161.441 109.897 -193.582
202103 -59.304 111.754 -69.929
202106 -38.014 114.631 -43.700
202109 -41.310 115.734 -47.036
202112 -30.621 117.630 -34.304
202203 -33.596 121.301 -36.497
202206 -51.093 125.017 -53.855
202209 -11.282 125.227 -11.872
202212 10.762 125.222 11.325
202303 -12.889 127.348 -13.337
202306 -6.969 128.729 -7.134
202309 -6.709 129.860 -6.808
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acorda Therapeutics  (FRA:CDG) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Acorda Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (FRA:CDG) Business Description

Traded in Other Exchanges
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines